Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
about
Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costsThe Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the LiteratureOpioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteriaProtocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.Abuse and misuse of antidepressantsCurrent and future development of extended-release, abuse-deterrent opioid formulations in the United States.Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.Exploring social work student education: The effect of a harm reduction curriculum on student knowledge and attitudes regarding opioid use disorders.An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-AmericansPrescribers and pharmacists requests for prescription monitoring program (PMP) data: does PMP structure matter?Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependencePrescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone.Prevalence and Factors Associated with Multiple Provider Episodes in Texas: An Epidemiological Analysis of Prescription Drug Monitoring Program Data."Don't Judge a Book Its Cover": A Qualitative Study of Methadone Patients' Experiences of Stigma.Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use.Patient registries for substance use disordersCan we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.Prescription opioid misuse and its relation to injection drug use and hepatitis C virus infection: protocol for a systematic review and meta-analysis.Trends in prescription of opioids from 2003-2009 in persons with knee osteoarthritisInfluences of motivational contexts on prescription drug misuse and related drug problems.Prescription opioid abuse: a literature review of the clinical and economic burden in the United States.Increases in body mass index following initiation of methadone treatment.Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent populationUrban vs. rural differences in prescription opioid misuse among adults in the United States: informing region specific drug policies and interventions.Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?Potential radiating effects of misusing substances among medical patients receiving brief intervention.Preoperative Opioid Misuse is Associated With Increased Morbidity and Mortality After Elective Orthopaedic Surgery.Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid DependenceSocial Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter.Tobacco Smoking, Nicotine Dependence, and Patterns of Prescription Opioid Misuse: Results From a Nationally Representative SampleBridging waitlist delays with interim buprenorphine treatment: initial feasibility.Comparing characteristics of prescription painkiller misusers and heroin users in the United StatesWhere Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural CountiesEstimating the health care burden of prescription opioid abuse in five European countriesInterim treatment: Bridging delays to opioid treatment access.The effect of intermittent alcohol vapor or pulsatile heroin on somatic and negative affective indices during spontaneous withdrawal in Wistar rats.
P2860
Q21284753-E1F6384B-0FB7-4309-9635-52728E1E4C91Q26741943-575B4AB2-6CA2-4ECB-8CC9-D1274A0E003DQ26778626-8B948A83-157A-4477-B56F-A33EC60B8ED2Q27318074-355FD242-5B61-4709-94BE-742D8F23D4BFQ27691354-D6873CEE-D376-42C9-8483-A13347858161Q30240248-0F7A99FA-C59F-4B32-B838-EA7B02A403C4Q30253083-379E38AE-0FCD-4F7D-B4BA-787FC7265E43Q30277261-9E22193D-2660-4147-93F7-5D09E95D4F9FQ30402982-EADF3A9C-E40E-406B-BB52-844878928963Q30543145-0E7829FC-3063-4393-9112-04D30108ED2BQ30629097-7B26C777-6BA7-4051-B6F9-FF3F452A491CQ30830475-1877E1D5-7941-498D-8BBC-B0B4674B6E95Q30831694-116FB339-5FC1-4867-B35F-37F1BE98CBB6Q30855550-AA40844F-8854-4BC0-80C6-EF20F52B4E12Q31131823-1762A58B-E775-4E48-9F9E-78F137F158F9Q31136904-93B740BD-12E2-4CA3-9A20-6B4E4C056F07Q33583856-2C556D11-AD5E-4946-8A9E-8CBF1E8ADAC5Q33760418-4E9D2C21-EFE0-4A05-97B3-4188AA573E82Q33842156-7F29991C-93EA-464B-881E-D84142D56F1AQ33968724-3930705E-80B0-439B-A2A9-4056453224FAQ34041421-D6956661-AB5C-4EE7-AB0F-9E688478CC9FQ34153684-10185B0D-59B1-4D72-A1C4-0C1ACBF646B8Q34255114-7F0249CD-5F27-4AC5-8CF0-978B1BD6B3D9Q34603740-F9C89797-D5B5-4FD9-9013-3EF49D9F34BBQ34751280-9D5E4AD5-34F4-4F65-83EB-90235AC66E4BQ35137700-A8A3FA60-2131-47C1-A3C3-810BD73229FDQ35154999-3F253587-4EC8-4AB0-909C-FC347C0B99D0Q35417479-39EF0FC9-97BE-45E9-9A67-A5E34DE3AD91Q35670689-3C4DF329-67A2-4CEA-93B4-26ED5B5F3EC5Q35685040-1495987C-A3BD-4E5C-AD4D-17DECFDB0B47Q35689351-09EC1AA2-4AC1-4B58-ADBC-826F6C312580Q35751878-E9F5EA0C-4883-4D1A-A117-E1278F45B89CQ35889429-35BAB79A-BD6A-46D7-8D62-2875DA1329E1Q35974919-B30457AB-590F-4B79-89DF-687A1E0B5C2AQ36021346-0AC3E1D2-91C2-4640-B02C-7DF4F4C7C2EEQ36021812-795CC7B0-6BA4-4B60-AFC6-F7A29A211711Q36054084-6879F1DD-D7EA-406F-888F-F4454E24B137Q36079375-CADF6160-A416-471A-B0AD-85CFE6383B13Q36117597-87AD701A-BCA5-4A8C-8442-9C928972106EQ36164923-69B89117-835B-455F-BEA3-9619082FFF6E
P2860
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
@en
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
@nl
type
label
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
@en
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
@nl
prefLabel
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
@en
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
@nl
P2093
P2860
P1433
P1476
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
@en
P2093
Alan G White
Carl L Roland
Howard G Birnbaum
Jody M Cleveland
Matt Schiller
Tracy Waldman
P2860
P304
P356
10.1111/J.1526-4637.2011.01075.X
P577
2011-03-10T00:00:00Z